Nexalin Technology Inc. has announced the publication of an independent, peer-reviewed case report in The American Journal on Addictions evaluating the company's 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. The case was conducted at the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, using Nexalin's non-invasive device, which delivered a 15 mA current at 77.5 Hz for 40 minutes per session. The study, registered on ClinicalTrials.gov (Identifier: NCT06195995), reported significant clinical improvement and sustained abstinence following treatment. The authors concluded that larger, controlled trials are warranted to further evaluate the device's efficacy in treating addiction comorbidities and other psychiatric disorders. These results have already been published and presented in the peer-reviewed journal.